aminopeptidas
n
target
molecul
scirrhou
gastric
cancer
conclus
data
suggest
suitabl
cell
surfac
candid
target
antibodydrug
therapi
scirrhou
gastric
cancer
summari
background
scirrhou
gastric
cancer
associ
periton
dissemin
advanc
lymph
node
metastasi
earli
stage
prognosi
still
poor
studi
aim
analyz
candid
molecul
target
therapi
scirrhou
gastric
cancer
search
moleculesmetabol
activ
might
predominantli
express
subpopul
scirrhou
gastric
cancer
cell
might
function
cancer
stem
cell
marker
result
purpos
investig
express
variou
cell
surfac
marker
aldehyd
dehydrogenas
aldh
activ
analys
show
scirrhou
gastric
cancer
cell
line
heterogen
express
epcam
express
uniformli
moreov
total
cell
popul
express
aldh
enzym
activ
subpopul
cell
strongli
posit
aldh
also
express
high
level
known
cancer
stem
cell
marker
cell
express
high
level
show
lower
sensit
cancer
drug
cisplatin
cell
low
level
contrast
high
subpopul
sensit
aminopeptidas
n
inhibitor
bestatin
term
antibodydrug
therapi
highli
cytotox
toward
cell
cytotox
antiepcamimmunotoxin
although
preval
gastric
carcinoma
recent
shown
gradual
decreas
cancer
still
account
signific
proport
cancerrel
death
japan
earli
detect
prevent
metastasi
cancer
essenti
order
improv
cure
rate
scirrhou
gastric
cancer
known
diffus
infiltr
carcinoma
borrmann
typeiv
carcinoma
liniti
plasticatyp
carcinoma
character
clinic
worst
prognosi
among
variou
type
gastric
cancer
frequent
associ
metastas
lymph
node
periton
dissemin
scirrhou
gastric
cancer
repres
approxim
gastric
carcinoma
show
surviv
rate
less
compar
type
gastric
cancer
variou
treatment
chemotherapi
hormon
therapi
hyperthermia
immunotherapi
test
effect
periton
metastasi
scirrhou
gastric
cancer
result
unsatisfactori
chemotherapi
play
signific
role
treatment
gastric
cancer
howev
prognosi
advanc
gastric
cancer
still
poor
treatment
usual
unsuccess
therefor
urgent
need
develop
effect
treatment
patient
stem
cell
constitut
sourc
cell
popul
tissu
organ
exhibit
selfrenew
abil
multidifferenti
potenti
case
cancer
subpopul
cancer
cell
exhibit
properti
stem
cell
also
present
cancer
tissu
socal
cancer
stem
cell
csc
first
report
acut
leukemia
later
becam
clear
csc
also
present
solid
tumor
breast
cancer
brain
tumor
csc
propos
root
caus
cancer
growth
drugresist
attempt
identifi
csc
made
base
express
cell
surfac
molecul
intracellular
metabol
activ
analysi
primari
tumor
specimen
establish
cell
line
current
report
definit
csc
marker
digest
cancer
colorect
cancer
liver
cancer
pancreat
cancer
among
variou
cell
surfac
marker
identif
csc
haraguchi
et
al
identifi
function
marker
use
identifi
potenti
dormant
liver
csc
howev
clear
definit
csc
marker
upper
gastrointestin
cancer
esophagu
stomach
cancer
first
aim
studi
therefor
determin
contribut
scirrhou
gastric
cancer
cell
line
analyz
cell
cell
surfac
antigen
metabol
enzym
activ
consid
possibl
candid
csc
marker
use
flow
cytometri
second
aim
studi
assess
whether
antibodymedi
drugtoxin
conjug
immunotoxin
target
toward
scirrhou
gastric
cancer
would
show
enhanc
antitumor
effect
scirrhou
gastric
cancer
scirrhou
gastric
cancer
cell
line
previous
establish
ascit
fluid
patient
scirrhou
gastric
carcinoma
stomach
adenocarcinoma
signetr
cell
carcinoma
katoiii
obtain
jcrb
cell
bank
osaka
japan
cell
maintain
medium
sigma
st
loui
mo
supplement
fetal
calf
serum
gibco
life
technolog
grand
island
ny
antibiot
sodium
pyruv
gibco
cultur
maintain
c
atmospher
co
air
propag
low
adhes
cultur
bottom
plastic
dish
follow
antibodi
use
flow
cytometr
analysi
cell
antiepcamp
ebiosci
san
diego
ca
biolegend
san
diego
ca
cell
incub
indic
antibodi
min
wash
twice
pb
contain
fc
flow
cytometr
analysi
perform
use
facscalibur
bd
immunocytometri
system
franklin
lake
nj
aldehyd
dehydrogenas
aldh
activ
cancer
cell
assay
use
aldefluor
substrat
accord
manufactur
protocol
stemcel
technolog
vancouv
canada
specimen
analyz
aldh
activ
counterstain
appropri
dilut
nonviabl
cell
elimin
use
propidium
iodid
sigma
specif
flow
gate
aldh
posit
cell
set
use
control
sampl
isol
tumor
cell
aldh
activ
inhibit
diethylaminobenzaldehyd
deab
subsequ
flow
cytometri
run
use
identifi
popul
cell
high
aldh
activ
aldh
high
express
surfac
marker
aminopeptidas
n
apn
separ
cell
variou
cell
surfac
level
cell
suspens
incub
purifi
antibodi
lowendotoxin
azidefre
biolegend
microbead
bound
antimous
igg
miltenyi
biotech
bergisch
gladbach
germani
ice
hour
wash
pb
cell
place
automac
cell
separ
miltenyi
biotech
accord
manufactur
instruct
cell
high
low
level
sort
collect
separ
sort
cell
wash
resuspend
test
cancer
drug
sensit
cell
plate
flat
micropl
cellswel
twofold
dilut
seri
cisplatin
cddp
initi
concentr
gml
fourfold
dilut
seri
bestatin
ubenimex
initi
concentr
gml
made
cell
cultur
indic
concentr
drug
c
co
day
viabl
cell
count
stain
alamarblu
reagent
abd
serotec
oxford
uk
data
analyz
repres
use
graphpad
prism
softwar
ver
cell
seed
densiti
cellswel
cultur
plate
cell
incub
antiepcam
isotyp
control
igg
gml
subsequ
saporinconjug
antimous
igg
ab
mabzap
advanc
target
system
san
diego
ca
ad
concentr
vari
ngml
cell
viabil
determin
day
use
alamarblu
reagent
first
examin
cell
express
variou
cell
surfac
molecul
includ
previous
report
csc
marker
other
shown
fig
absolut
express
cell
uniformli
posit
contrast
show
heterogen
express
next
examin
express
variou
human
gastric
scirrhou
adenocarcinoma
cell
line
fig
found
express
scirrhou
gastric
cell
line
welldifferenti
tubular
adenocarcinoma
cell
line
poorli
differenti
adenocarcinoma
cell
line
katoiii
deriv
signetr
cell
carcinoma
also
neg
interestingli
highli
metastat
cell
line
isol
respect
strongli
posit
sever
studi
report
reliabl
cell
surfac
marker
identifi
csc
examin
whether
would
use
identif
csc
scirrhou
gastric
cancer
howev
express
weakli
fig
result
suggest
might
use
certain
subpopul
scirrhou
gastric
cancer
cell
cell
popul
highli
express
aldh
previous
report
consid
characterist
csc
gastric
cancer
next
examin
aldh
express
two
differ
scirrhou
gastric
cancer
cell
line
katoiii
use
flow
cytometri
found
cell
express
aldh
wherea
katoiii
cell
respect
express
aldh
fig
data
support
aldh
express
marker
identif
csc
cell
investig
whether
popul
cell
express
high
aldh
activ
could
also
express
cell
surfac
csc
candid
identifi
cell
evalu
flow
cytometri
use
fluoresc
substrat
assay
aldh
activ
use
peconjug
antibodi
cell
surfac
molecul
popul
cell
strongli
posit
aldh
also
express
high
level
fig
correl
found
aldh
activ
level
level
data
shown
investig
drug
sensit
high
low
subpopul
cell
analysi
growth
inhibitori
effect
differ
concentr
cisplatin
wide
use
clinic
anticanc
agent
shown
fig
high
subpopul
show
lower
sensit
cisplatin
ci
ngml
low
cell
ci
ngml
order
confirm
contribut
drug
resist
scirrhou
cancer
cell
line
test
inhibitori
effect
inhibitor
bestatin
growth
shown
fig
high
subpopul
show
higher
sensit
bestatin
low
cell
result
may
support
drugresist
properti
cancer
cell
might
correl
high
level
investig
potenti
abil
intern
toxic
drug
cell
next
examin
cytotox
antibodi
drug
conjug
target
epcam
ab
cell
prior
experi
confirm
express
epcam
flow
cytometri
fig
shown
fig
c
saporinconjug
second
antibodi
cytotox
toward
cell
bound
ab
saporinconjug
antibodi
dosedepend
manner
howev
saporinconjug
second
antibodi
cytotox
toward
cell
antiepcam
ab
bound
data
show
suitabl
cell
surfac
candid
target
antibodydrug
therapi
scirrhou
gastric
cancer
numer
report
shown
small
subset
cancer
cell
bear
drugresist
stem
cell
properti
cell
refer
cancer
stem
stemlik
cell
csc
tumoriniti
cell
tic
csc
identif
first
attempt
acut
leukemia
later
attempt
mani
type
cancer
howev
csc
valid
scirrhou
gastric
cancer
cell
line
li
et
al
report
csc
could
identifi
pancreat
cancer
base
high
express
esa
cell
surfac
studi
shown
marker
csc
breast
colon
lung
ovari
pancrea
prostat
cancer
addit
marker
overexpress
cell
surfac
transport
protein
includ
relat
multidrugresist
properti
csc
therefor
tri
identifi
csc
scirrhou
gastric
cancer
cell
line
use
antibodi
variou
cell
surfac
cd
antigen
use
flow
cytometri
unexpectedli
cell
surfac
marker
either
express
uniformli
express
except
heterogen
express
heterogen
express
also
found
cell
interestingli
highli
metastat
cell
line
deriv
parent
caus
fatal
cancer
periton
bloodi
ascit
express
extrem
high
level
contrast
katoiii
weak
tumorigen
nude
mice
lack
express
anticip
tumorigen
properti
scirrhou
gastric
cancer
cell
line
might
relat
high
popul
anoth
commonlyus
cancer
normal
hematopoiet
stem
cell
marker
aldh
intracellular
enzym
involv
retino
acid
ethanol
metabol
also
resist
alkyl
cancer
drug
shown
high
aldh
express
correl
tumorigen
potenti
poor
prognosi
breast
cancer
patient
therefor
determin
express
metabol
marker
aldh
cell
previou
report
shown
express
altern
splice
variant
strongli
contribut
cellular
resist
variou
anticanc
drug
base
data
unlik
aldh
activ
correl
express
cell
surfac
molecul
scirrhou
gastric
cancer
cell
line
howev
observ
approxim
cell
express
high
level
aldh
activ
cell
popul
enrich
aldh
activ
almost
ident
high
popul
significantli
greater
number
high
aldh
high
cell
popul
surviv
chemotherapi
cddp
rel
low
aldh
low
cell
popul
preliminari
data
express
cell
increas
treatment
anticanc
agent
includ
doxorubicin
decitabin
data
shown
data
suggest
one
candid
use
marker
enrich
cell
popul
contain
put
csc
abund
myeloid
differenti
antigen
also
express
nonhematopoiet
cell
sever
report
shown
relationship
cancer
thought
play
import
role
protein
digest
also
decompos
collagen
confer
extracellular
matrix
metastas
abil
tumor
cell
moreov
express
endotheli
cell
process
neovascular
contribut
enhanc
tumor
metastasi
invas
indic
express
candid
contribut
poor
prognosi
cancer
inde
inhibitor
properti
enter
anticanc
clinic
trial
thu
bestatin
ubenimex
origin
describ
immunomodul
inhibit
aminopeptidas
activ
sever
clinic
trial
target
toward
hematolog
malign
conduct
agent
surviv
benefit
ubenimex
demonstr
acut
myeloid
leukemia
lymphoma
addit
variou
clinic
studi
conduct
ubenimex
nonhematopoiet
cancer
lung
bladder
head
neck
esophagu
skin
shown
fig
bestatin
exhibit
antiprolif
effect
cell
vitro
high
cell
popul
sensit
bestatin
low
cell
furthermor
curcumin
natur
phenol
product
isol
turmer
report
inhibit
inhibit
curcumin
greater
bestatin
consequ
curcumin
current
investig
effect
patient
breast
prostat
pancreat
cancer
result
indic
associ
cell
growth
invas
metastasi
variou
cancer
suggest
suitabl
target
anticanc
therapi
antibodi
target
cell
surfac
molecul
overexpress
cancer
cell
compar
normal
cell
effect
cancer
therapi
current
therapeut
monoclon
antibodi
approv
clinic
applic
cancer
novel
strategi
conjug
drug
radioact
agent
antibodi
particularli
promis
therapeut
approach
sever
drugconjug
antibodi
specif
current
test
clinic
trial
howev
antibodi
bind
cell
surfac
molecul
suitabl
use
therapeut
drug
conjug
order
deliveri
drugcytotox
agent
bound
antibodi
cell
essenti
drugconjug
antibodi
intern
togeth
cytotox
agent
cancer
cell
far
investig
regard
use
drugconjug
antibodi
therapi
order
investig
possibl
analyz
cytotox
immunotoxin
saporin
conjug
antibodi
treatment
cell
vitro
shown
fig
effici
vitro
toxin
deliveri
cell
higher
antibodi
combin
saporinconjug
antimous
igg
control
igg
efficaci
increas
saporinconjug
antibodi
dosedepend
manner
compar
inhibitor
bestatin
curcumin
advantag
antibodi
conjug
therapi
specif
effect
scirrhou
gastric
cancer
efficaci
antibodi
toxin
deliveri
contrast
antiepcam
antibodi
thu
although
epcam
highli
express
cell
improv
toxin
deliveri
compar
control
igg
use
antiepcam
antibodi
quit
low
low
effici
epcamtarget
immunotoxin
might
due
lack
intern
properti
antiepcam
antibodi
higher
efficaci
antibodi
may
due
fact
character
cellular
receptor
coronaviru
cytomegaloviru
infect
indic
effici
deliv
viru
protein
cell
antibodi
function
artifici
ligand
mimic
natur
viral
ligand
high
low
cell
popul
cell
indic
antibodymedi
intracellular
deliveri
immunotoxin
may
therapeut
effect
scirrhou
gastric
cancer
also
plan
investig
therapeut
effect
immunoliposom
contain
curcumin
scirrhou
gastric
cancer
xenograft
conclus
data
studi
suggest
possibl
certain
cell
popul
scirrhou
gastric
cancer
drugresist
express
may
also
function
target
cancer
therapi
howev
investig
need
clarifi
contribut
csc
function
corrobor
role
drugresist
tumor
activ
analysi
clinic
specimen
scirrhou
gastric
cancer
author
declar
compet
interest
sort
chemosensit
assay
research
support
part
grantinaid
scientif
research
b
grant
ministri
educ
cultur
sport
scienc
technolog
japan
